Cochrane · systematic review · CD008661
Modafinil for people with schizophrenia or related disorders
Ortiz-Orendain, J, Covarrubias-Castillo, SA, Vazquez-Alvarez, AO, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 5 · 71.4%Low 1 · 14.3%Moderate 1 · 14.3%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Modafinil compared to placebo for people with schizophrenia or related disorders
Population: schizophrenia or related disorders
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mental state: clinically important change in general mental state ‐ worsening psychosis Modafinil vs placebo | RR 0.91 [0.28, 2.98] | 6 studies · 209 participants | Low Downgraded: imprecision, indirectness |
Cognitive function: average endpoint score** Modafinil vs placebo | no estimate extracted | 1 study · 48 participants | Very low Downgraded: indirectness |
Adverse effect/event(s) ‐ serious adverse events Modafinil vs placebo | RR 0.84 [0.06, 12.42] | 1 study · 35 participants | Very low Downgraded: indirectness |
Global state: clinically important change in global state Modafinil vs placebo | RR 6.36 [0.94, 43.07] | 1 study · 21 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Leaving the study early ‐ for any reason Modafinil vs placebo | RR 1.26 [0.63, 2.53] | 9 studies · 357 participants | Moderate Downgraded: risk of bias, imprecision, indirectness |
Quality of life: average endpoint score** Modafinil vs placebo | no estimate extracted | 1 study · 20 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Service use: hospital admission Modafinil vs placebo | RR 0.84 [0.06, 12.42] | 1 study · 35 participants | Very low Downgraded: risk of bias, imprecision, indirectness |